New vaccine aims to shield sickle cell kids from deadly infections
NCT ID NCT07247188
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children and teens with sickle cell disease, aged 2 to 17. The goal is to see if it's safe and helps the body make antibodies better than the current 20-valent vaccine. Participants get one shot and are monitored for side effects and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
21-valent pneumococcal conjugate vaccine (PCV21)
What this could lead to
If successful, this vaccine could provide better protection against pneumococcal infections for children with sickle cell disease, who are at high risk.
What could go wrong
This is a phase 3 trial, but it's still relatively small (100 participants). The new vaccine may not prove more effective than the existing one, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site # 2140001
RECRUITINGSanto Domingo, Dominican Republic
-
Site # 2140003
RECRUITINGSanto Domingo, Dominican Republic
-
Site # 8400001
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Site # 8400002
RECRUITINGAtlanta, Georgia, 30322, United States
-
Site # 8400003
RECRUITINGOmaha, Nebraska, 68114, United States
-
Site # 8400004
RECRUITINGHouston, Texas, 77030, United States
-
Site # 8400006
RECRUITINGAtlanta, Georgia, 30310, United States